Immune checkpoint inhibitors (ICIs) prevent repressive interactions that inhibit T cell–mediated cancer killing, for example, by using antibodies to block cancer cell ligand PD-L1 from binding to PD-1 on CD8+ T cells (67). This evidence concerns the gene CD274 and cancer.